A Randomized, Open-Label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants
Latest Information Update: 08 Jan 2021
At a glance
- Drugs Abatacept (Primary)
- Indications Alopecia areata; Common variable immunodeficiency; Diffuse scleroderma; Graft-versus-host disease; Interstitial lung diseases; Juvenile rheumatoid arthritis; Lupus nephritis; Myositis; Nephrotic syndrome; Polymyalgia rheumatica; Psoriatic arthritis; Pulmonary sarcoidosis; Rheumatoid arthritis; Sjogren's syndrome
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 28 Nov 2020 Status changed from not yet recruiting to completed.
- 29 Oct 2018 New trial record